A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer

Clinical trial NCT03602495 · TERMINATED

Trial details

NCT number: NCT03602495
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Differentiated Thyroid Cancer

Start date: 2018-08-29
Primary completion: 2021-02-28
Enrollment: 204

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.